Nikko Asset Management Americas Trimmed Pbr Us (PBR) Stake; Oncobiologics (ONS) Shorts Down By 2.56%

June 20, 2017 - By Winifred Garcia

Nikko Asset Management Americas Inc decreased Pbr Us (PBR) stake by 14.39% reported in 2016Q4 SEC filing. Nikko Asset Management Americas Inc sold 115,800 shares as Pbr Us (PBR)’s stock declined 16.81%. The Nikko Asset Management Americas Inc holds 688,700 shares with $6.96M value, down from 804,500 last quarter. Pbr Us now has $49.74B valuation. The stock declined 3.33% or $0.27 reaching $7.85 per share. About 16.64M shares traded. Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) has risen 39.56% since June 20, 2016 and is uptrending. It has outperformed by 22.86% the S&P500.

Oncobiologics Incorporated (NASDAQ:ONS) had a decrease of 2.56% in short interest. ONS’s SI was 79,900 shares in June as released by FINRA. Its down 2.56% from 82,000 shares previously. With 39,500 avg volume, 2 days are for Oncobiologics Incorporated (NASDAQ:ONS)’s short sellers to cover ONS’s short positions. The SI to Oncobiologics Incorporated’s float is 0.76%. About 62,959 shares traded or 1.58% up from the average. Oncobiologics Inc (NASDAQ:ONS) has 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Nikko Asset Management Americas Inc increased Baker Hughes Inc (NYSE:BHI) stake by 21,100 shares to 205,345 valued at $13.34 million in 2016Q4. It also upped Kimberly (NYSE:KMB) stake by 7,800 shares and now owns 10,500 shares. Gulfport Energy Corp (NASDAQ:GPOR) was raised too.

Among 14 analysts covering Petroleo Brasileiro Petrobras SA (NYSE:PBR), 3 have Buy rating, 4 Sell and 7 Hold. Therefore 21% are positive. Petroleo Brasileiro Petrobras SA had 32 analyst reports since August 7, 2015 according to SRatingsIntel. Raymond James downgraded Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) on Thursday, May 19 to “Underperform” rating. The company was maintained on Thursday, October 6 by Morgan Stanley. maintained the stock with “Underweight” rating in Monday, October 10 report. Barclays Capital downgraded it to “Underweight” rating and $9 target in Wednesday, July 13 report. The stock of Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) earned “Underperform” rating by Credit Suisse on Friday, September 11. Credit Suisse maintained the stock with “Neutral” rating in Monday, September 26 report. The stock of Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR) earned “Underperform” rating by JP Morgan on Thursday, February 4. Credit Suisse maintained it with “Buy” rating and $11 target in Wednesday, April 19 report. Bank of America downgraded the shares of PBR in report on Friday, September 11 to “Neutral” rating. Morgan Stanley upgraded it to “Equal-Weight” rating and $5.60 target in Tuesday, March 22 report.

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $29.09 million. The Firm is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It currently has negative earnings. It is focused on monoclonal antibodies in the disease areas of immunology and oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: